Veru (VERU)
(Delayed Data from NSDQ)
$0.91 USD
-0.04 (-4.08%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $0.92 +0.01 (0.58%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VERU 0.91 -0.04(-4.08%)
Will VERU be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VERU based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VERU
Veru Inc. (VERU) Just Flashed Golden Cross Signal: Do You Buy?
Baxter (BAX) to Report Q1 Earnings: What's in the Cards?
VERU: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Veru (VERU) a New Buy Stock
After Plunging -15.61% in 4 Weeks, Here's Why the Trend Might Reverse for Veru Inc. (VERU)
Bio-Rad Laboratories (BIO) to Post Q4 Earnings: What Awaits?
Other News for VERU
Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism
VERU Stock Earnings: Veru Beats EPS, Misses Revenue for Q1 2024
Veru management to meet virtually with B. Riley
Veru management to meet virtually with B. Riley
Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions